PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia

Schizophrenia Research

Volumn 101, Issue 1-3, 2008, Pages 36-49

  Fatemi, S Hossein ^a   King, David P ^b   Reutiman, Teri J ^a   Folsom, Timothy D ^a   Laurence, Jessica A ^a   Lee, Susanne ^a   Fan, Yu Ti ^b   Paciga, Sara A ^b   Conti, Marco ^c   Menniti, Frank S ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bipolar disorder; Major depression; Phosphodiesterase 4B; Polymorphisms; Schizophrenia

Indexed keywords

CYCLIC AMP; ISOENZYME; PHOSPHODIESTERASE; PHOSPHODIESTERASE 4B;

AFRICAN AMERICAN; ARTICLE; AUTOPSY; BIPOLAR DISORDER; BRAIN LEVEL; BRAIN NERVE CELL; BRAIN TISSUE; CAUCASIAN; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; BRAIN; CHI-SQUARE DISTRIBUTION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 42749089914     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.01.029     Document Type: Article

References (62)

1. Ahmed T., and Frey J.U. Expression of the specific type IV phosphodiesterase gene PDE4B3 during different phases of long-term potentiation in single hippocampal slices of rats in vitro. Neuroscience 117 3 (2003) 627-638
2. Ahmed T., and Frey J.U. Phosphodiesterase 4B (PDE4B) and cAMP-level regulation within different tissue fractions of rat hippocampal slices during long-term potentiation in vitro. Brain Res. 1041 2 (2005) 212-222
3. Andreasen N.C., O'Leary D.S., Cizadlo T., Arndt S., Rezai K., Ponto L.L., Watkins G.L., and Hichwa R.D. Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc. Natl. Acad. Sci. U.S.A 93 18 (1996) 9985-9990
4. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 2 (2005) 263-265
5. Beauregard M., Leroux J.M., Bergman S., Arzoumanian Y., Beaudoin G., Bourgouin P., and Stip E. The functional neuroanatomy of major depression: an fMRI study using an emotional activation paradigm. Neuroreport 9 14 (1998) 3253-3258
6. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75 4 (1995) 725-748
7. Beavo J.A., Conti M., and Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46 3 (1994) 399-405
8. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 3 (2006) 488-520
9. Bolger G.B. Molecular biology of cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal. 6 8 (1994) 851-859
10. Braun N.N., Reutiman T.J., Lee S., Folsom T.D., and Fatemi S.H. Expression of Phosphodiesterase 4 is altered in brain of subjects with autism. NeuroReport 18 17 (2007) 1841-1844
11. Cherry J.A., and Davis R.L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. 407 2 (1999) 287-301
12. Conti M., and Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63 (1999) 1-38
13. Conti M., Swinnen J.V., Tsikalas K.E., and Jin S.L. Structure and regulation of the rat high-affinity cyclic AMP phosphodiesterases. A family of closely related enzymes. Adv. Second Messenger Phosphopro. Res. 25 (1992) 87-99
14. D'Sa C., Eisch A.J., Bolger G.B., and Duman R.S. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur. J. Neurosci. 22 6 (2005) 1463-1475
15. Dlaboga D., Hajjhussein H., and O'Donnell J.M. Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram. Brain Res. 1096 1 (2006) 104-112
16. Farooqui S.M., Zhang K., Makhay M., Jackson K., Farooqui S.Q., Cherry J.A., and O'Donnell J.M. Noradrenergic lesions differentially alter the expression of two subtypes of low Km cAMP-sensitive phosphodiesterase type 4 (PDE4A and PDE4B) in rat brain. Brain Res. 867 1-2 (2000) 52-61
17. Fatemi S.H., Stary J.M., Earle J.A., Araghi-Niknam M., and Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr. Res. 72 2-3 (2005) 109-122
18. Fleischhacker W.W., Hinterhuber H., Bauer H., Pflug B., Berner P., Simhandl C., Wolf R., Gerlach W., Jaklitsch H., Sastre-y-Hernández M., et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26 1-2 (1992) 59-64
19. Häfner H., Maurer K., Trendler G., an der Heiden W., Schmidt M., and Könnecke R. Schizophrenia and depression: challenging the paradigm of two separate diseases-a controlled study of schizophrenia, depression and healthy controls. Schizophr. Res. 77 1 (2005) 11-24
20. Halene T.B., and Siegel S.J. PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia?. Drug Discov. Today 12 19-20 (2007) 870-878
21. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 1 (2005) 40-68
22. Hashimoto R., Numakawa T., Ohnishi T., Kumamaru E., Yagasaki Y., Ishimoto T., Mori T., Nemoto K., Adachi N., Izumi A., Chiba S., Noguchi H., Suzuki T., Iwata N., Ozaki N., Taguchi T., Kamiya A., Kosuga A., Tatsumi M., Kamijima K., Weinberger D.R., Sawa A., and Kunugi H. Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum. Mol. Genet. 15 20 (2007) 3024-3033
23. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic. Acid Res. Mol. Biol. 69 (2001) 249-315
24. Houslay M.D., and Adams D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370 Pt 1 (2003) 1-18
25. Houslay M.D., Sullivan M., and Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 44 (1998) 225-342
26. Jurevicius J., Skeberdis V.A., and Fischmeister R. Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following beta2-adrenergic stimulation of ICa,L in frog ventricular myocytes. J. Physiol. 551 Pt 1 (2003) 239-252
27. Iona S., Cuomo M., Bushnik T., Naro F., Sette C., Hess M., Shelton E.R., and Conti M. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol. Pharmacol. 53 1 (1998) 23-32
28. Kanes S.J., Tokarczyk J., Siegel S.J., Bilker W., Abel T., and Kelly M.P. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neurosci. 144 1 (2007) 239-246
29. Konarski J.Z., McIntyre R.S., Grupp L.A., and Kennedy S.H. Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?. J. Psychiatry Neurosci. 30 3 (2004) 178-186
30. Krüger S., Seminowicz D., Goldapple K., Kennedy S.H., and Mayberg H.S. State and trait influences on mood regulation in bipolar disorder: blood flow differences with an acute mood challenge. Biol Psychiatry 54 11 (2003) 1274-1283
31. Le Hir H., Nott A., and Moore M.J. How introns influence and enhance eukaryotic gene expression. Trends Biochem. Sci. 28 4 (2003) 215-220
32. Liotti M., Mayberg H.S., McGinnis S., Brannan S.L., and Jerabek P. Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am. J. Psychiatry 159 11 (2002) 1830-1840
33. Liu Y.L., Fann C.S., Liu C.M., Chen W.J., Wu J.Y., Hung S.I., Chen C.H., Jou Y.S., Liu S.K., Hwang T.J., Hsieh M.H., Ouyang W.C., Chan H.Y., Chen J.J., Yang W.C., Lin C.Y., Lee S.F., and Hwu H.G. A single nucleotide polymorphism fine mapping study of chromosome 1q42.1 reveals the vulnerability genes for schizophrenia, GNPAT and DISC1: Association with impairment of sustained attention. Biol. Psychiatry 60 6 (2006) 554-562
34. Loeber R.T., Gruber S.A., Cohen B.M., Renshaw P.F., Sherwood A.R., and Yurgelun-Todd D.A. Cerebellar blood volume in bipolar patients correlates with medication. Biol Psychiatry 51 5 (2002) 370-376
35. Loughney K., and Ferguson K. Identification and quantification of PDE isoforms and subtypes by molecular biological methods. In: Schudt C., Dent G., and Rabe K.F. (Eds). Phosphodiesterase Inhibitors (1996), Academic Press, San Diego 1-19
36. Lynch M.J., Baillie G.S., Mohamed A., Li X., Maisonneuve C., Klussmann E., van Heeke G., and Houslay M.D. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J. Biol. Chem. 280 39 (2005) 33178-33189
37. Maxwell C.R., Kanes S.J., Abel T., and Siegel S.J. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129 1 (2004) 101-107
38. Menniti F.S., Faraci W.S., and Schmidt C.J. Phosphodiesterases in the CNS. Nature Rev. Drug Disc. 5 8 (2006) 660-670
39. Michel J.J., and Scott J.D. AKAP mediated signal transduction. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 235-257
40. Millar J.K., Pickard B.S., Mackie S., James R., Christie S., Buchanan S.R., Malloy M.P., Chubb J.E., Huston E., Baillie G.S., Thomson P.A., Hill E.V., Brandon N.J., Rain J.C., Camargo L.M., Whiting P.J., Houslay M.D., Blackwood D.H., Muir W.J., and Porteous D.J. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310 5751 (2005) 1128-1129
41. Mongillo M., McSorley T., Evellin S., Sood A., Lissandron V., Terrin A., Huston E., Hannawacker A., Lohse M.J., Pozzan T., Houslay M.D., and Zaccolo M. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ. Res. 95 1 (2004) 67-75
42. Mueser K.T., and McGurk S.R. Schizophrenia. Lancet 363 9426 (2004) 2063-2072
43. McGue M., and Gottesman I.I. The genetic epidemiology of schizophrenia and the design of linkage studies. Eur. Arch. Psychiatr. neurol. sci. 240 3 (1991) 174-181
44. Murdoch H., Mackie S., Collins D.M., Hill E.V., Bolger G.B., Klussmann E., Porteous D.J., Millar J.K., and Houslay M.D. Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J. Neurosci. 27 35 (2007) 9513-9524
45. Nasrallah H.A., Jacoby C.G., and McCalley-Whitters M. Cerebellar atrophy in schizophrenia and mania. Lancet 1 8229 (1981) 1102
46. O'Donnell J.M., and Zhang H.T. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci. 25 3 (2004) 158-163
47. Phillips M.L., Drevets W.C., Rauch S.L., and Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol. Psychiatry 54 5 (2003) 515-528
48. Picard H., Amado I., Mouchet-Mages S., Olie J.-P., and Krebs M.-O. The Role of the Cerebellum in Schizophrenia: an Update of Clinical, Cognitive, and Functional Evidences. Schizophr Bull 34 1 (2008) 155-172
49. Porteous D.J., and Millar J.K. Disrupted in schizophrenia 1: building brains and memories. Trends Mol. Med. 12 6 (2006) 255-261
50. Qu M., Tang F., Yue W., Ruan Y., Lu T., Liu Z., Zhang H., Han Y., Zhang D., Wang F., and Zhang D. Positive association of the Disrupted-in-Schizophrenia-1 gene (DISC1) with schizophrenia in the Chinese Han population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144 3 (2007) 266-270
51. Rose G.M., Hopper A., De Vivo M., and Tehim A. Phosphodiesterase inhibitors for cognitive enhancement. Curr. Pharm. Des. 11 26 (2005) 3329-3334
52. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., and Coyle J.T. Neurobiology of schizophrenia. Neuron 52 1 (2006) 139-153
53. Sette C., and Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase: involvement of serine 54 in the enzyme activation. J. Biol. Chem. 271 28 (1996) 16526-16534
54. Shepherd M., McSorley T., Olsen A.E., Johnston L.A., Thomson N.C., Baillie G.S., Houslay M.D., and Bolger G.B. Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochem. J. 370 (2003) 429-438
55. Smith K.A., Ploghaus A., Cowen P.J., McCleery J.M., Goodwin G.M., Smith S., Tracey I., and Matthews P.M. Cerebellar responses during anticipation of noxious stimuli in subjects recovered from depression. Functional magnetic resonance imaging study. Br. J. Psychiatry 181 (2002) 411-415
56. Sullivan P.F., Kendler K.S., and Neale M.C. Schizophrenia is a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 60 12 (2003) 1187-1192
57. Szpirer C., Szpirer J., Riviere M., Swinnen J., Vicini E., and Conti M. Chromosomal localization of the human and rat genes (PDE4D and PDE4B) encoding the cAMP-specific phosphodiesterases 3 and 4. Cytogenet. Cell Genet. 69 1-2 (1995) 11-14
58. Takahashi M., Terwilliger R., Lane C., Mezes P.S., Conti M., and Duman R.S. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci. 19 2 (1999) 610-618
59. Torrey E.F., Webster M., Knable M., Johnston N., and Yolken R.H. The Stanley Foundation brain collection and neuropathology consortium. Schizophr. Res. 44 2 (2000) 151-155
60. Zeller E., Stief H.J., Pflug B., and Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 17 6 (1984) 188-190
61. Zhang H.T., Huang Y., Jin S.L., Frith S.A., Suvarna N., Conti M., and O'Donnell J.M. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology. 27 4 (2002) 587-595
62. Zhang, H.T., Huang, Y., Masood, A., Stolinski, L.R., Li, Y., Zhang, L., Dlaboga, D., Jin, S.L., Conti, M., O'Donnell, J.M., in press. Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B). Neuropsychopharmacology.